PL EN


Preferences help
enabled [disable] Abstract
Number of results
2012 | 66 | 5 | 62–66
Article title

Pentraksyna 3 – nowy wskaźnik zapalenia

Content
Title variants
EN
Pentraxin 3 – new marker of infl ammation
Languages of publication
PL
Abstracts
EN
In this review the authors describe long pentraxin 3 (PTX3), a protein from the pentraxin superfamily (like CRP), associated with local processes of infl ammation, especially related to blood vessels. Recent papers have revealed the relationship between PTX3 levels and atherosclerosis, therefore also with ischaemic heart disease and acute coronary syndromes. In many other diseases, PTX3 can play a diagnostic role, and may also be involved in the pathogenesis process, i.e. COPD, asthma, renal failure, PCO and sepsis. We describe the molecule itself, its clinical signifi cance and role in pathogenesis, as we understand it today, in some clinical areas.
PL
W niniejszym przeglądzie autorzy opisują pentraksynę 3 (PTX3), białko z nadrodziny pentraksyn (tak jak białko C-reaktywne – CRP), związane z lokalnymi procesami zapalnymi, szczególnie dotyczącymi naczyń krwionośnych. Współczesne badania pokazują związki między poziomem PTX3 a miażdżycą, a więc również chorobą niedokrwienną serca i ostrymi zespołami wieńcowymi. Innymi grupami schorzeń, w których PTX3 może odgrywać rolę diagnostyczną, a być może również uczestniczyć w patogenezie, są schorzenia układu oddechowego (przewlekła obturacyjna choroba płuc – POChP i astma), choroby nerek (w tym szczególnie niewydolność), PCO, ciężkie infekcje bakteryjne.
Discipline
Year
Volume
66
Issue
5
Pages
62–66
Physical description
References
  • 1. Bottazzi B., Bastone A., Doni A. i wsp. The long pentraxin PTX3 as a link among innate immunity, infl ammation, and female fertility. J. Leukoc. Biol. 2006; 79: 909–912.
  • 2. Mantovani A., Garlanda C., Bottazzi B. i wsp. The long pentraxin PTX3 in vascular pathology. Vascul. Pharmacol. 2006 Nov; 45: 326–330.
  • 3. Savchenko A., Imamura M., Ohashi R. i wsp. Expression of pentraxin 3 (PTX3) in human atherosclerotic lesions. J. Pathol. 2008; 215: 48–55.
  • 4. Norata G.D., Garlanda C., Catapano A.L. The long pentraxin-3; a modulator of the immunoinfl ammatory response in atherosclerosis and cardiovascular diseases. Trends Cardiovasc. Med. 2010; 20: 35–40.
  • 5. Inoue K., Sugiyama A., Reid P.C. i wsp. Establishment of a high sensitivity plasma assay for human pentraxin3 as a marker for unstable angina pectoris. Arterioscler. Thromb. Vasc. Biol. 2007; 27: 161–167.
  • 6. Peri G., Introna M., Corradi D. i wsp. PTX3, A prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation 2000; 8; 102: 636–641.
  • 7. Mallat Z., Tedgui A. HDL, PTX3, and vascular protection. Arterioscler. Thromb. Vasc. Biol. 2008; 28: 809–811.
  • 8. Jylhävä J., Haarala A., Kähönen M. i wsp. Pentraxin 3 (PTX3) is associated with cardiovascular risk factors: the Health 2000 Survey. Clin. Exp. Immunol. 2011; 162: 211–217.
  • 9. Welt F.G., Tso C., Edelman E.R. i wsp. Leukocyte recruitment and expression of chemokines following diff erent forms of vascular injury. Vasc. Med. 2003; 8: 1–7.
  • 10. Latini R., Maggioni A.P., Peri G. i wsp. Prognostic signifi cance of the long pentraxin PTX3 in acute myocardial infarction. Circulation 2004; 110: 2349–2354.
  • 11. Suzuki S., Takeshi Y., Niizeki T. i wsp. Pentraxin 3 a new marker for vascular infl ammation, predicts adverse clinical outcomes in patients with heart failure. Am. Heart J. 2008; 155: 75–81.
  • 12. Matsubara J., Sugiyama S., Nozaki T. i wsp. Pentraxin 3 Is a New Infl ammatory Marker Correlated With Left Ventricular Diastolic Dysfunction and Heart Failure With Normal Ejection FractionFREE. J. Am. Coll. Cardiol. 2011; 57: 861–869.
  • 13. Latini R., Gullestad L., Masson S. i wsp. Pentraxin-3 in chronic heart failure: the CORONA and GISSI-HF trials. Eur. J. Heart Fail. 2012; 14: 992–999.
  • 14. Zhang J., Shan L., Koussih L. i wsp. Pentraxin 3 (PTX3) Expression in Allergic Asthmatic Airways: Role in Airway Smooth Muscle Migration and Chemokine Production. PLoS One 7(4): 2012, e34965.
  • 15. Camozzi M., Rusnati M., Bugatti A. i wsp. Identifi cation of anantiangiogenic FGF2-binding site in the N terminus of the soluble pattern recognition receptor PTX3. J. Biol. Chem. 2006; 281: 22605 –22613.
  • 16. Firestein G. S, Zvaifl er N. J. Rheumatoid arthritis: a disease of disordered immunity. W: Infl ammation basic principles and clinical correlates. J.I. Gallin, I.M. Goldstein, K. Willis. 2nd edn. New York: Raven Press, 1992.
  • 17. Pauwels N.S., Bracke K.R., Maes T. i wsp. Cigarette smoke induces PTX3 expression in pulmonary veins of mice in an IL-1 dependent manner. Respir. Res. 2010; 11: 134.
  • 18. Luchetti M.M., Piccinini G., Matovani A. i wsp. Expression and production of the long pentraxin PTX3 in rheumatoid arthritis (RA). Clin. Exp. Immunol. 2000; 119: 196–202.
  • 19. Huttunen R., Hurme M., Aittoniemi J. i wsp. High Plasma Level of Long Pentraxin 3 (PTX3) Is Associated with Fatal Disease in Bacteremic Patients: AProspective Cohort Study. PLoS One |2011; 6: e17653.
  • 20. Tong M., Carrero J.J., Qureshi A.R., Anderstam B., Heimburger O. Plasma pentraxin- 3 in patients with chronic kidney disease: association with renal function, protein-energy wasting, cardiovascular disease and mortality. Clin. J. Am. Soc. Nephrol. 2007; 2: 889–897.
  • 21. Yilmaz M.I., Axelsson J., Sonmez A., Carrero J.J. Saglam M. Eff ect of renin angiotensin system blockade on Pentraxin 3 levels in type 2 diabetic patients with proteinuria. Clin. J. Am. Soc. Nephrol. 2009; 4: 535–541.
  • 22. Libby P., Rocha V.Z. Obesity, infl ammation and atherosclerosis. Nat. Rev. Cardiol. 2009; 6: 399–409.
  • 23. Aydogdu A., Tasci I., Tapan S. i wsp. High plasma level of long Pentraxin 3 is associated with insulin resistance in women with polycystic ovary syndrome. Gynecol. Endocrinol. 2012, 28; 722–725.
Document Type
article
Publication order reference
YADDA identifier
bwmeta1.element.psjd-d748f5b7-3382-4e81-8122-b280bcb0fc4a
Identifiers
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.